fig11
Figure 11. Sequential administration of esterase-responsive Podo-NP, redox-sensitive CbP-NP, and a CD40 agonist enhances the antitumor T cell response. (A) Bioresponsive Podo-NP and CbP-NP; (B) Improving immunotherapy outcomes with sequential antiangiogenesis and chemotherapy; (C) Proposed Podo prodrug bioconversion via esterase-catalyzed cascade hydrolysis. Reproduced from Ref.[96] with permission from © 2020 American Chemical Society.
